Qiagen N.V.
QGEN- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001015820
No open-market purchases or sales by Qiagen N.V. insiders were filed in the last 90 days; 337 institutions reported holding it in 13F filings for Q2 2026, worth $5.68B in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Qiagen N.V. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Of which not filed for Q2 2021 | Q2 2021 | Change |
|---|---|---|---|---|
| Holders | 276 | 2 | 259 | −15 |
| Shares | 122.8M | 3.34M | 123.6M | +4.11M (+3.4%) |
| Value | $5.97B | $162.7M | $5.98B | +$173.8M (+3.0%) |
2 institutions that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (33)
Institutions that held Qiagen N.V. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (48)
Institutions that held Qiagen N.V. at the end of Q1 2021 and filed for Q2 2021 without it.
Not filed for Q2 2021 yet (2)
Institutions that held Qiagen N.V. at the end of Q1 2021 and haven't filed a 13F for Q2 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Amundi Asset Management US, Inc. | 3,334,312 | $162.3M |
| Fairpointe Capital LLC | 7,247 | $352.0K |